Rigel Pharmaceuticals Inc
RIGLFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Rigel Pharmaceuticals Inc Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 17 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 24, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Rigel Pharmaceuticals Inc's recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2024-02-05 · RODRIGUEZ RAUL R: Larger than all 20 other insider sales of Common Stock on file. SEC filing
- 2024-02-02 · RODRIGUEZ RAUL R: Larger than 19 of the 20 other insider sales of Common Stock on file. SEC filing
- 2023-02-06 · RODRIGUEZ RAUL R: Larger than 18 of the 20 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-22 | Ali-Jackson Kamil · Director | Common Stock | S — Open market or private sale | −2,500 | 35.00 | SEC filing |
| 2026-05-26 | Ali-Jackson Kamil · Director | Common Stock | S — Open market or private sale | −2,500 | 29.17 | SEC filing |
| 2026-02-20 | MOOS WALTER H · Director | Common Stock | S — Open market or private sale | −4,000 | 36.36 | SEC filing |
| 2025-02-05 | Furey Raymond J. · EVP, GC, CCO & Corp Sec | Common Stock | S — Open market or private sale | −1,339 | 21.93 | SEC filing |
| 2025-02-05 | RODRIGUEZ RAUL R · CEO, President | Common Stock | S — Open market or private sale | −4,400 | 21.93 | SEC filing |
| 2025-02-05 | Schorno Dean L · EVP & Chief Financial Officer | Common Stock | S — Open market or private sale | −1,734 | 21.93 | SEC filing |
| 2025-02-05 | Santos David A · EVP, Chief Commercial Officer | Common Stock | S — Open market or private sale | −1,796 | 21.93 | SEC filing |
| 2025-02-04 | Furey Raymond J. · EVP, GC, CCO & Corp Sec | Common Stock | S — Open market or private sale | −1,448 | 20.92 | SEC filing |
Showing 8 of 11 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-17 | Santos David A · EVP, Chief Commercial Officer | Employee Stock Option (right to buy) | A — Grant, award, or other acquisition | +7,394 | SEC filing |
| 2026-06-17 | Rojkjaer Lisa · EVP, Chief Medical Officer | Employee Stock Option (right to buy) | A — Grant, award, or other acquisition | +9,375 | SEC filing |
| 2026-06-17 | Furey Raymond J. · EVP, GC, CCO & Corp Sec | Employee Stock Option (right to buy) | A — Grant, award, or other acquisition | +7,394 | SEC filing |
| 2026-06-17 | Schorno Dean L · EVP & Chief Financial Officer | Employee Stock Option (right to buy) | A — Grant, award, or other acquisition | +7,394 | SEC filing |
| 2026-06-17 | Rojkjaer Lisa · EVP, Chief Medical Officer | Employee Stock Option (right to buy) | A — Grant, award, or other acquisition | +7,394 | SEC filing |
| 2026-06-17 | RODRIGUEZ RAUL R · CEO, President | Employee Stock Option (right to buy) | A — Grant, award, or other acquisition | +31,700 | SEC filing |
| 2026-06-01 | Schorno Dean L · EVP & Chief Financial Officer | Employee Stock Option (right to buy) | M — Exercise or conversion of derivative security | −1,200 | SEC filing |
| 2026-06-01 | Schorno Dean L · EVP & Chief Financial Officer | Common Stock | M — Exercise or conversion of derivative security | +2,181 | SEC filing |
Showing 8 of 30 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.